

Commercialization of synthetic biology platform (Logomix)



City	Year of Establishment	Founder
Harumi, Chuo-ku, Tokyo	2019	Yasunori Aizawa Taiki Ishikura

Partner VC	Latest round of Fundraising	Valuation
JAFCO Group Co., Ltd.	Series A	Non-Disclosure

Contact Information :
e-mail: admin@logomix.bio

Website : <https://logomix.bio/>

○ Business Plan

Construction of industrial microorganisms/cells with enhanced property using our proprietary large-scale genome engineering platform technology.

With the technology, we address the SDGs challenges with our partner companies.

○ Research Outline

In this R&D effort, we upgrade our genome engineering platform by the following measures:

1. Constructing a high-throughput evaluation system for the genome-engineered organisms
2. Building an efficient system for creating genome-engineered organisms
3. Developing a lab-scale evaluation protocol that can replicate scale-up evaluation.

Business Area/Field	Research Period	Research Amount	International collaborative technology demonstration
Healthcare	STS 2024~2025FY	JPY 352 million	—

As of May,2024